Certain microbial compositions can enhance the body’s ability to fight melanoma by improving the response to immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies, suggesting that onco-microbiotic therapies could be tailored to optimize treatment outcomes [72]. The gene discussed is CTLA4; the disease is melanoma.